Skip to main content

Table 4 Differences in rs12696304 and rs2736100 genotyping between controls and patients with ESRD

From: The telomerase gene polymorphisms, but not telomere length, increase susceptibility to primary glomerulonephritis/end stage renal diseases in females

Patients
(M + F)
Odds ratio
(95% CI)
P valueControls
(M only)
Patients
(M only)
Odds ratio
(95% CI)
P valueControls
(F only)
Patients
(F only)
Odds ratio
(95% CI)
P
value
516 (100%)  289 (100%)300 (100%)  226 (100%)216 (100%)  
51 (9.9)1.0 (ref.) 32 (11.1)31 (10.3)1.0 (ref.) 24 (10.6)20 (9.3)1.0 (ref.) 
186 (36.0)0.916 (0.598–1.403)0.686119 (41.2)108 (36.0)0.937 (0.536–1.637)0.819104 (46.0)78 (36.1)0.900(0.464–1.745)0.755
279 (54.1)1.298 (0.855–1.970)0.219138 (47.7)161 (53.7)1.204 (0.699–2.074)0.50298 (43.4)118 (54.6)1.445 (0.753–2.771)0.266
237 (45.9)1.0 (ref.) 151 (52.3)139 (46.3)1.0 (ref.) 128 (56.6)98 (45.4)1.0 (ref.) 
279 (54.1)1.392 (1.089–1.778)0.010138 (47.7)161 (53.7)1.267 (0.917–1.752)0.17698 (43.4)118 (54.6)1.573 (1.080–2.289)0.023
288 (27.9)1.0 (ref.) 183 (31.7)170 (28.3)1.0 (ref.) 152 (33.6)118 (27.3)1.0 (ref.) 
744 (72.1)1.245 (1.031–1.503)0.022395 (68.3)430 (71.7)1.172 (0.913–1.504)0.213300 (66.4)314 (72.7)1.348 (1.011–1.798)0.042
520 (100%)  289 (100%)297 (100%)  226 (100%)223 (100%)  
156 (30.0)1.0 (ref.) 93 (32.2)104 (35.0)1.0 (ref.) 65 (28.8)52 (23.3)1.0 (ref.) 
248 (47.7)0.977 (0.737–1.295)0.873136 (47.1)134 (45.1)0.881 (0.610–1.273)0.500121 (53.5)114 (51.1)1.178 (0.754–1.839)0.472
116 (22.3)1.175 (0.830–1.662)0.36360 (20.7)59 (19.9)0.879 (0.558–1.387)0.58040 (17.7)57 (25.6)1.781 (1.033–3.070)0.037
560 (53.8)1.0 (ref.) 322 (55.7)342 (57.6)1.0 (ref.) 251 (55.5)218 (48.9)1.0 (ref.) 
480 (46.2)1.075 (0.904–1.278)0.415256 (44.3)252 (42.4)0.927 (0.736–1.168)0.519201 (44.5)228 (51.1)1.306 (1.005–1.698)0.046
  1. ESRD End-stage renal disease, M male, F female, CI confidence interval; italic P value: statistically significant
\